EPI-326 / EpiBiologics - LARVOL DELTA

EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit (Businesswire) - "EpiBiologics...is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit....These data are being presented this morning at the American Association for Cancer Research (AACR) Annual Meeting 2024....EpiTACs drove robust in vitro tumoricidal activity in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) models, independent of KRAS or EGFR mutational status. In vivo tumor models demonstrated EpiTACs degraded mutant EGFR and disrupts downstream signaling, suppressing tumor growth and increasing survival beyond osimertinib standard of care."

Preclinical • Non Small Cell Lung Cancer